Two receptors made tirzepatide a breakthrough. Retatrutide added a third—and raised the separately reported topline number to 28.3% average weight loss.
RETATRUTIDE ADDS A THIRD GLUCAGON SIGNAL AND HAS THE LARGER TOPLINE WEIGHT-LOSS RESULT; TIRZEPATIDE HAS FDA APPROVAL AND A LONGER TRACK RECORD.
That is the useful answer in July 2026. Retatrutide looks stronger on its highest published trial number. Tirzepatide has the real-world advantage today: approved finished medicines, a longer clinical record, and more established use.
Compare Retatrutide and Tirzepatide specifications →
Which one stands out?
The choice depends on whether you value the newest triple-receptor results or the longer, FDA-approved clinical track record.
Choose Tirzepatide for
The proven dual-receptor path
GIP + GLP-1 action, FDA-approved finished medicines, and a longer clinical record.
Choose Retatrutide for
The triple-receptor research story
GIP + GLP-1 + glucagon action and the larger separately reported topline result.
Watch next
TRIUMPH-5
The direct Phase 3 comparison is underway, with primary completion estimated for December 2026.
Retatrutide vs tirzepatide at a glance
| Comparison | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor signals | 2: GIP + GLP-1 | 3: GIP + GLP-1 + glucagon |
| Highest major obesity-trial average | 20.9% at 72 weeks in SURMOUNT-1 | 28.3% at 80 weeks in TRIUMPH-1 |
| U.S. status in July 2026 | Active ingredient in FDA-approved finished medicines | Investigational; U.S. submission planned for Q1 2027 |
| Clinical track record | Longer | Newer |
| Certiva vial specifications | 5–120 mg | 5–60 mg |
| Published Certiva 2026 COA | 99.699% HPLC purity | 99.699% HPLC purity |
The weight-loss figures come from separate trials, so they are not a clean head-to-head score. Still, they answer the question buyers and readers are asking: retatrutide has posted the larger topline number, while tirzepatide remains the more established option.
What is the main difference?
Tirzepatide is a dual agonist. It activates:
- GIP; and
- GLP-1.
Retatrutide keeps those two signals and adds a third:
- glucagon.
In plain English, tirzepatide sends two metabolic signals. Retatrutide sends three. The extra glucagon signal is designed to add another pathway connected with energy use and metabolism.
That does not make every three-signal molecule automatically better than every two-signal molecule. It does explain why retatrutide is getting so much attention—and why its Phase 3 numbers matter.
Which one reported more weight loss?
Retatrutide has the larger published topline average.
In the Phase 3 TRIUMPH-1 trial, the highest-dose retatrutide group averaged 28.3% weight loss at 80 weeks. In an extension for participants who started with a BMI of at least 35, the average reached 30.3% at 104 weeks.
In the peer-reviewed Phase 3 SURMOUNT-1 trial, the highest-dose tirzepatide group averaged 20.9% weight loss at 72 weeks. The 10 mg group averaged 19.5%, and the 5 mg group averaged 15.0%.
| Trial | Molecule | Highest-dose average | Time |
|---|---|---|---|
| TRIUMPH-1 | Retatrutide | −28.3% | 80 weeks |
| SURMOUNT-1 | Tirzepatide | −20.9% | 72 weeks |
These results make retatrutide the clear leader on the largest separately reported average. The trials used different designs, timelines, and participants, so TRIUMPH-5 is the study that can settle the direct comparison.
For the newest retatrutide data in people with type 2 diabetes, severe obesity, and heart disease, read our July 2026 Retatrutide Phase 3 results guide.
Is there a true head-to-head trial?
Yes. TRIUMPH-5 directly compares retatrutide with tirzepatide in adults with obesity.
The Phase 3 study includes about 800 participants and measures weight change at 80 weeks. Its estimated primary completion is December 2026.
This is important because it removes much of the guesswork created by comparing separate trials. Until the result arrives, the fairest conclusion is:
- retatrutide has the larger topline result;
- tirzepatide has the longer clinical record and FDA-approved finished products;
- the direct winner is now being tested.
Which one has the longer clinical track record?
Tirzepatide does.
The FDA approved the first tirzepatide medicine for type 2 diabetes in 2022 and approved Zepbound for chronic weight management in 2023. That gives tirzepatide more completed clinical work and real-world experience.
Retatrutide is newer, but its development is moving quickly. Lilly reported three major Phase 3 weight-loss results in 2026, including TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3, and said it plans a U.S. submission in the first quarter of 2027.
So the simple tradeoff is established dual action versus newer triple action.
What side effects were reported?
Both trial programs most often reported digestive side effects.
Commonly reported events included:
- nausea;
- diarrhea;
- constipation; and
- vomiting.
In the cited trials, these events were generally mild to moderate and were most common while doses were being increased. That gives the two molecules a similar broad side-effect pattern, although only the direct TRIUMPH-5 data can show how their rates compare under the same study conditions.
Retatrutide vs tirzepatide for research buyers
The clinical story creates demand. The vial, batch documents, and supplier response determine whether a research order is useful.
Certiva supplies:
- Tirzepatide: 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, and 120 mg;
- Retatrutide: 5, 10, 15, 20, 30, 40, 50, and 60 mg;
- standard packaging: 10 vials per box; and
- bulk and custom quantities: available by inquiry.
Our published 2026 batch reports list 99.699% HPLC purity for both research references. Always match the COA to the lot being offered.
View the published Tirzepatide COA · View the published Retatrutide COA
Need help reading the reports? Use our five-minute peptide COA guide. Buyers comparing suppliers can also review our seven-point peptide supplier checklist.
The bottom line
RETATRUTIDE ADDS A THIRD GLUCAGON SIGNAL AND HAS THE LARGER TOPLINE WEIGHT-LOSS RESULT; TIRZEPATIDE HAS FDA APPROVAL AND A LONGER TRACK RECORD.
Retatrutide is the more exciting new research story: three receptor signals and up to 28.3% average weight loss at 80 weeks in TRIUMPH-1. Tirzepatide is the more established story: dual-receptor action, FDA-approved finished medicines, and a longer clinical record.
The next major answer should come from TRIUMPH-5, the direct comparison now scheduled to reach primary completion in December 2026.
Request specifications, current COAs, and a quote
Tell Certiva which molecule, vial specification, quantity, destination country, and documents you need. We will reply with current availability, applicable batch information, lead time, bulk options, and a quote.
View Tirzepatide specifications · View Retatrutide specifications · See published COAs · Visit the Certiva facility page
Request both current COAs + a comparison quote →
Sources and further reading
- Lilly: TRIUMPH-1 Phase 3 results, May 21, 2026
- Lilly: TRIUMPH-2 and TRIUMPH-3 results, July 23, 2026
- New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity
- FDA: Approval of Zepbound for chronic weight management
- ClinicalTrials.gov: TRIUMPH-5, NCT06662383
Frequently asked questions
Which is better, retatrutide or tirzepatide?
RETATRUTIDE ADDS A THIRD GLUCAGON SIGNAL AND HAS THE LARGER TOPLINE WEIGHT-LOSS RESULT; TIRZEPATIDE HAS FDA APPROVAL AND A LONGER TRACK RECORD.
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates two receptor systems, GIP and GLP-1. Retatrutide activates those same two systems and adds the glucagon receptor, making it a triple agonist.
Which reported more weight loss, retatrutide or tirzepatide?
Retatrutide reported the larger topline average in separate trials—28.3% at 80 weeks in TRIUMPH-1 versus 20.9% at 72 weeks for the highest tirzepatide dose in SURMOUNT-1. These were not head-to-head results.
Is retatrutide or tirzepatide FDA approved?
Tirzepatide is the active ingredient in FDA-approved finished prescription medicines. Retatrutide remains investigational, and Lilly plans to submit it for U.S. approval in the first quarter of 2027.
Do retatrutide and tirzepatide have similar side effects?
The most common side effects reported in trials of both molecules were digestive, including nausea, diarrhea, constipation, and vomiting. They were generally mild to moderate in the cited trials.
Is there a retatrutide vs tirzepatide head-to-head trial?
Yes. The Phase 3 TRIUMPH-5 trial directly compares retatrutide with tirzepatide over 80 weeks. Its estimated primary completion is December 2026, so no final head-to-head result is available yet.
Can buyers see Certiva COAs before ordering retatrutide or tirzepatide?
Yes. Buyers can review Certiva's published batch COAs and request the current applicable report, vial specifications, availability, bulk options, and a destination-based quote before ordering.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.